Continued from Part 1...
We greatly appreciate the FDA’s efforts to increase the number of generic drug approvals and take action on applications in the backlog.
What some people also might not understand is that not all generic medicines approved by the FDA make it to market.
WASHINGTON, D.C. (February 12, 2018) In its newest white paper, released today, the Association for Accessible Medicines (AAM) finds that generics and biosimilars continue to provide savings for patients, but that uninterrupted patient access to these affordable prescription medicines is at risk.
Patient health and well-being depends on the uninterrupted availability of lower-cost generic and biosimilar medicines. Moreover, as patients live longer the importance of a robust and sustainable generic and biosimilar medicines industry becomes only that much more important. Policymakers must act quickly to ensure continued saving and market-based competition, as well as prevent shortages, for future availability of affordable medicines. This requires: